Moreover, up to 20% of ER-positive/HER2-negative metastatic BC are intrinsically resistant to CDK4/6 inhibitors, and nearly all patients, whose tumor initially responded to these drugs, will develop acquired resistance. This evidence concerns the gene ESR1 and breast cancer.